From U S Carolina: Personalized therapy for advanced lung cancer

http://www.ncbi.nlm.nih.gov/pubmed/22176813

Lung Cancer. 2011 Dec 14. [Epub ahead of print]
The role of molecular analyses in the era of personalized therapy for advanced NSCLC.
Tanner NT, Pastis NJ, Sherman C, Simon GR, Lewin D, Silvestri GA.
Source
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, PO Box 250630, Charleston, SC 29425, United States.

Abstract
Platinum-based doublet chemotherapy is the traditional treatment of choice for advanced non-small cell lung cancer (NSCLC); however, the efficacy of these regimens has reached a plateau. Increasing evidence demonstrates that patients with sensitizing mutations in the epidermal growth factor receptor (EGFR) experience improved progression-free survival and response rates with first-line gefitinib or erlotinib therapy relative to traditional platinum-based chemotherapy, while patients with EGFR-mutation negative tumors gain greater benefit from platinum-based chemotherapy. These results highlight the importance of molecular testing prior to the initiation of first-line therapy for advanced NSCLC. Routine molecular testing of tumor samples represents an important paradigm shift in NSCLC therapy and would allow for individualized therapy in specific subsets of patients. As these and other advances in personalized treatment are integrated into everyday clinical practice, pulmonologists will play a vital role in ensuring that tumor samples of adequate quality and quantity are collected in order to perform appropriate molecular analyses to guide treatment decisions. This article provides an overview of clinical trial data supporting molecular analysis of NSCLC, describes specimen acquisition and testing methods currently in use, and discusses future directions of personalized therapy for patients with NSCLC.